Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival.
Tettero JM, Ngai LL, Bachas C, Breems DA, Fischer T, Gjertsen BT, Gradowska P, Griskevicius L, Janssen JJWM, Juliusson G, Maertens J, Manz MG, Pabst T, Passweg J, Porkka K, Valk PJM, Löwenberg B, Ossenkoppele GJ, Cloos J. Tettero JM, et al. Among authors: bachas c. Haematologica. 2023 Oct 1;108(10):2794-2798. doi: 10.3324/haematol.2022.282639. Haematologica. 2023. PMID: 37021540 Free PMC article. No abstract available.
Procedures for the expansion of CD14(+) precursors from acute myeloid leukemic cells to facilitate dendritic cell-based immunotherapy.
van den Ancker W, Wijnands PG, Ruben JM, Westers TM, Punt B, Bachas C, Ravenshorst N, van Wetering S, Kruisbeek AM, Bontkes HJ, Ossenkoppele GJ, van de Loosdrecht AA, de Gruijl TD. van den Ancker W, et al. Among authors: bachas c. Immunotherapy. 2013 Nov;5(11):1183-90. doi: 10.2217/imt.13.125. Immunotherapy. 2013. PMID: 24188673 Clinical Trial.
Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting.
Hanekamp D, Snel AN, Kelder A, Scholten WJ, Khan N, Metzner M, Irno-Consalvo M, Sugita M, de Jong A, Oude Alink S, Eidhof H, Wilhelm M, Feuring-Buske M, Slomp J, van der Velden VHJ, Sonneveld E, Guzman M, Roboz GJ, Buccisano F, Vyas P, Freeman S, Bachas C, Ossenkoppele GJ, Schuurhuis GJ, Cloos J. Hanekamp D, et al. Among authors: bachas c. Br J Haematol. 2020 Sep;190(6):891-900. doi: 10.1111/bjh.16594. Epub 2020 Apr 2. Br J Haematol. 2020. PMID: 32239670 Free PMC article.
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.
Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, Tettero JM, Bachas C, Baer C, Béné MC, Bücklein V, Czyz A, Denys B, Dillon R, Feuring-Buske M, Guzman ML, Haferlach T, Han L, Herzig JK, Jorgensen JL, Kern W, Konopleva MY, Lacombe F, Libura M, Majchrzak A, Maurillo L, Ofran Y, Philippe J, Plesa A, Preudhomme C, Ravandi F, Roumier C, Subklewe M, Thol F, van de Loosdrecht AA, van der Reijden BA, Venditti A, Wierzbowska A, Valk PJM, Wood BL, Walter RB, Thiede C, Döhner K, Roboz GJ, Cloos J. Heuser M, et al. Among authors: bachas c. Blood. 2021 Dec 30;138(26):2753-2767. doi: 10.1182/blood.2021013626. Blood. 2021. PMID: 34724563 Free PMC article.
Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party.
Tettero JM, Freeman S, Buecklein V, Venditti A, Maurillo L, Kern W, Walter RB, Wood BL, Roumier C, Philippé J, Denys B, Jorgensen JL, Bene MC, Lacombe F, Plesa A, Guzman ML, Wierzbowska A, Czyz A, Ngai LL, Schwarzer A, Bachas C, Cloos J, Subklewe M, Fuering-Buske M, Buccisano F. Tettero JM, et al. Among authors: bachas c. Hemasphere. 2021 Dec 22;6(1):e676. doi: 10.1097/HS9.0000000000000676. eCollection 2022 Jan. Hemasphere. 2021. PMID: 34964040 Free PMC article.
35 results